Literature DB >> 15297135

Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma.

Brigitta G Baumert1, Salvador Villà, Gabriela Studer, René-Olivier Mirimanoff, J Bernard Davis, Klara Landau, Nicolas Ducrey, Jordi Arruga, Philippe Lambin, Alessia Pica.   

Abstract

BACKGROUND AND
PURPOSE: To report on the efficacy and follow-up of 23 patients with primary optic nerve sheath meningioma (ONSM) with fractionated stereotactic conformal radiotherapy (SCRT). PATIENTS AND METHODS: Between 1996 and 2003, 23 patients ( = 23 eyes) with ONSM were treated. Indications for primary stereotactic radiotherapy were tumour progression documented by imaging or symptoms (loss of vision, pain). All patients received SCRT with a median dose of 50.4Gy in 6 weeks.
RESULTS: After a median follow-up of 20 months (1-68 months) a 95% (21 of 22) visual control was seen: vision improved in 16 patients and remained stable in 5. For 13/16 patients improvement was documented already within 1-3 months after SCRT. Vision became worse in one patient. An improvement of pain was observed after radiotherapy in 6 patients as well as of proptosis in 1 patient. For 1 patient pain was persistent after SCRT. In one patient 4 years after SCRT a radiation retinitis and vitreous haemorrhage was seen.
CONCLUSIONS: Fractionated stereotactic radiotherapy improves vision, often shortly after treatment, and is thus a viable treatment option for this tumour entity.

Entities:  

Mesh:

Year:  2004        PMID: 15297135     DOI: 10.1016/j.radonc.2004.04.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

Review 1.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

2.  High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma. A multicentre study.

Authors:  I Compter; K Zaugg; R M A Houben; J T A Dings; G Bosmans; C Buescher; M M H M E Anten; B G Baumert
Journal:  Strahlenther Onkol       Date:  2012-09-09       Impact factor: 3.621

Review 3.  Detection and treatment of optic nerve sheath meningioma.

Authors:  Mark L Moster
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

4.  Fractionated conformal radiotherapy for management of optic nerve sheath meningiomas: long-term outcomes of tumor control and visual function at a single institution.

Authors:  Philippe Metellus; Sumit Kapoor; Siddharth Kharkar; Sachin Batra; Juan F Jackson; Lawrence Kleinberg; Neil R Miller; Daniele Rigamonti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-17       Impact factor: 7.038

5.  Primary and Secondary Optic Nerve Sheath Meningioma.

Authors:  Elena Solli; Roger E Turbin
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-18

6.  Long-term outcome of moderate hypofractionated stereotactic radiotherapy for meningiomas.

Authors:  Ernesto Maranzano; Lorena Draghini; Michelina Casale; Fabio Arcidiacono; Paola Anselmo; Fabio Trippa; Cesare Giorgi
Journal:  Strahlenther Onkol       Date:  2015-10-21       Impact factor: 3.621

7.  Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors.

Authors:  M Kocher; H Treuer; M Hoevels; R Semrau; V Sturm; R-P Mueller
Journal:  Strahlenther Onkol       Date:  2012-12-20       Impact factor: 3.621

8.  Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas.

Authors:  Stefanie Milker-Zabel; Peter Huber; Wolfgang Schlegel; Jürgen Debus; Angelika Zabel-du Bois
Journal:  J Neurooncol       Date:  2009-04-01       Impact factor: 4.130

Review 9.  Meningioma: current treatment options and future directions.

Authors:  Kevin P McMullen; Volker W Stieber
Journal:  Curr Treat Options Oncol       Date:  2004-12

10.  Optic nerve sheath meningioma in the first decade of life: case report and review of the literature.

Authors:  Mário L R Monteiro; Allan Christian P Gonçalves; Sheila Aparecida C Siqueira; Eloísa M M Gebrim
Journal:  Case Rep Ophthalmol       Date:  2012-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.